Royalty Pharma (MEX:RPRX) Asset Impairment Charge : MXN0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Asset Impairment Charge?

Royalty Pharma's Asset Impairment Charge for the three months ended in Sep. 2024 was MXN0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was MXN0 Mil.

Royalty Pharma Asset Impairment Charge Historical Data

The historical data trend for Royalty Pharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Asset Impairment Charge Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

1,294.03

12,006.16

Royalty Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Royalty Pharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

Royalty Pharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPD:Germany

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.